SEC Company Response from BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796) (BCRX) — Jan 19, 2007
BIOCRYST PHARMACEUTICALS INC (BCRX) (CIK 0000882796)
Date: Jan. 19, 2007 · CIK: 0000882796 · Accession: 0000950134-07-000841
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-23186
Referenced dates: December 15, 2006
Letter
Via EDGAR and Overnight Courier Division of Corporation Finance BioCryst Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2005 Filed March 9, 2006 File No. 000-23186
Dear Mr. Rosenberg:
On behalf of BioCryst Pharmaceuticals, Inc. (the “Company”), please find the responses and the supplemental information requested orally by the Staff of the Securities and Exchange Commission (the “Staff”) in a telephone conversation on January 9, 2007 (the “Jan. 9 Comment”), with respect to the above-referenced Annual Report on Form 10-K of the Company. The responses and supplemental information provided herein in response to the Jan. 9 Comment are based upon conferences with representatives of the Company and other information supplied by its advisors. We have not independently verified the accuracy and completeness of such information.
As requested, the Company has revised the supplemental tabular disclosure previously provided to the Staff in the response letter dated December 15, 2006 (the “Dec. 15 Response Letter”), to quantify the categories of costs incurred under the “All other R&D expenses” category. The revised supplemental tabular disclosure is enclosed herewith as Exhibit B. The Company undertakes to include disclosure of the type enclosed with the Dec. 15 Response Letter as Exhibit A, as modified in accordance with Exhibit B enclosed herewith, in its Management’s Discussion and Analysis for future reporting periods, commencing with the Company’s Annual Report on Form 10-K for the year ended December 31, 2006.
Richard R. Plumridge 303.866.0583 rich.plumridge@hro.com
1700 Lincoln Street, Suite 4100 Denver, Colorado 80203-4541 tel 303.861.7000 fax 303.866.0200
Mr. Jim B. Rosenberg
January 19, 2007
Page 2
Please note that confidential treatment of the enclosed Exhibit B is requested under the Freedom of Information Act (“FOIA”). Accordingly, we have marked the enclosed Exhibit B with the legend “FOIA Confidential Treatment Requested.”
If you would like to discuss the responses above or any other matter, please contact the undersigned at (303) 866-0583 or Jennifer D’Alessandro at (303) 866-0635.
Sincerely,
/s/ Richard R. Plumridge
Show Raw Text
CORRESP
1
filename1.htm
corresp
DENVER
BOULDER
COLORADO SPRINGS
LONDON
LOS ANGELES
MUNICH
SALT LAKE CITY
SAN FRANCISCO
January 19, 2007
Via EDGAR and Overnight Courier
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D. C. 20549-6010
Re:
BioCryst Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2005
Filed March 9, 2006
File No. 000-23186
Dear Mr. Rosenberg:
On behalf of BioCryst Pharmaceuticals, Inc. (the “Company”), please find the responses and the
supplemental information requested orally by the Staff of the Securities and Exchange Commission
(the “Staff”) in a telephone conversation on January 9, 2007 (the “Jan. 9 Comment”), with respect
to the above-referenced Annual Report on Form 10-K of the Company. The responses and supplemental
information provided herein in response to the Jan. 9 Comment are based upon conferences with
representatives of the Company and other information supplied by its advisors. We have not
independently verified the accuracy and completeness of such information.
As requested, the Company has revised the supplemental tabular disclosure previously provided
to the Staff in the response letter dated December 15, 2006 (the “Dec. 15 Response Letter”), to
quantify the categories of costs incurred under the “All other R&D expenses” category. The revised
supplemental tabular disclosure is enclosed herewith as Exhibit B. The Company undertakes
to include disclosure of the type enclosed with the Dec. 15 Response Letter as Exhibit A,
as modified in accordance with Exhibit B enclosed herewith, in its Management’s Discussion
and Analysis for future reporting periods, commencing with the Company’s Annual Report on Form 10-K
for the year ended December 31, 2006.
Richard R. Plumridge 303.866.0583 rich.plumridge@hro.com
1700 Lincoln Street, Suite 4100 Denver, Colorado 80203-4541 tel 303.861.7000 fax 303.866.0200
Mr. Jim B. Rosenberg
January 19, 2007
Page 2
Please note that confidential treatment of the enclosed Exhibit B is requested under
the Freedom of Information Act (“FOIA”). Accordingly, we have marked the enclosed Exhibit B with the legend “FOIA Confidential Treatment Requested.”
If you would like to discuss the responses above or any other matter, please contact the
undersigned at (303) 866-0583 or Jennifer D’Alessandro at (303) 866-0635.
Sincerely,
/s/ Richard R. Plumridge
Richard R. Plumridge
cc:
Kei Ino
Jim Atkinson
Jon P. Stonehouse
Michael A. Darwin